Estimation of Prolactin and Some Biochemical Parameters in Some Psychotic Male Patients Treated with Risperidone in Tikrit City

Marwa Abdulsalam Kader

doi:10.55544/jrasb.2.2.5

Authors

Marwa Abdulsalam Kader Department of Biology, Science College, Tikrit University, IRAQ.

DOI:

https://doi.org/10.55544/jrasb.2.2.5

Keywords:

Risperidone, Prolactin, Total protein, AST, ALT

Abstract

The primary purpose of this research is to examine the impact of taking risperidone by psychotic individuals on serum levels of prolactin hormone as well as a few biochemical indicators (total protein and liver enzymes AST and ALT). The experiment required collecting fifty blood samples and dividing them into two groups: the first group consisted of normal, healthy persons who served as a control. In contrast, the second group consisted of psychotic patients treated with risperidone at a dosage of two milligrams per day. The findings of this study showed that There were significant increases in total protein content at levels (P≤ 0.05) of the group 2 compared to control, and there were significant gains in liver enzymes (AST and ALT) concentration range at levels (P ≤0.05) of the second group in comparison to the control group, and there were substantial improvements increases in prolactin hormone concentrations at levels (P≤ 0.05) of the second group in compared to control.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Folquitto, J. C., Barros, S. B., Pinto Junior, J. A., & Bottino, C. M. C. (2010). Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study. Dementia & Neuropsychologia, 4(1), 69–74. https://doi.org/10.1590/s1980-57642010dn40100012.

Raja, M. (2009). Pharmacotherapy update: Risperidone in the treatment of schizophrenia. Clinical Medicine. Therapeutics, 1. https://doi.org/10.4137/cmt.s1123.

Bernard, V., Young, J., & Binart, N. (2019). Prolactin — a pleiotropic factor in health and disease. Nature Reviews Endocrinology, 15(6), 356–365. https://doi.org/10.1038/s41574-019-0194-6.

Saleem, M.; Martin, H. and Coates, P. (2018). Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues. Clin Biochem Rev 39 (1) , pp:3-16.

Aboraya, A. ; Fullen, J. E.; Ponieman, B. L. ; Makela , E. H. and Latocha , M. (2004). Hyperprolactinemia Associated with Risperidone: A Case Report and Review of Literature. Psychiatry [November] , pp:29-31.

Sabria, K. (2017). Antipsychotic-induced hyperprolactinemia. https://doi.org/10.26226/morressier.58a41cf9d462b8028d8913e9.

Kalas, M. A., Chavez, L., Leon, M., Taweesedt, P. T., & Surani, S. (2021). Abnormal liver enzymes: A review for clinicians. World Journal of Hepatology, 13(11), 1688–1698. https://doi.org/10.4254/wjh.v13.i11.1688.

Gowda, S.; Desai, P. B.; Hull, V. V.; Math, A.A K. ; Vernekar, S. N. and Kulkarni , S. S. (2009). A review on laboratory liver function tests. Pan African Medical Journal (November).

Giannini, E. G. (2005). Liver enzyme alteration: A guide for Clinicians. Canadian Medical Association Journal, 172(3), 367–379. https://doi.org/10.1503/cmaj.1040752.

Wright, T. M., & Vandenberg, A. M. (2007). Risperidone- and quetiapine-induced cholestasis. Annals of Pharmacotherapy, 41(9), 1518–1523. https://doi.org/10.1345/aph.1k145.

Qinyu , L.V. and Zhenghui ,Y. I. (2018). Antipsychotic Drugs and Liver Injury. Shanghai Archives of Psychiatry, 2018, Vol. 30, No. 1, pp:47-51.

Margari, L., Matera, E., Petruzzelli, M. G., Simone, M., Lamanna, A. L., Pastore, A., Palmieri, V. O., & Margari, F. (2015). Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. International Clinical Psychopharmacology, 30(2), 103–108. https://doi.org/10.1097/yic.0000000000000063.

Balijepalli, C., Druyts, E., Zoratti, M. J., Wu, P., Kanji, S., Rabheru, K., Yan, K., & Thorlund, K. (2018). Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and Schizophrenia Spectrum Disorders: A network meta-analysis. Schizophrenia Research and Treatment, 2018, 1–9. https://doi.org/10.1155/2018/1543034.

Kunwar, A. R., & Megna, J. L. (2003). Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Annals of Pharmacotherapy, 37(2), 206–208. https://doi.org/10.1177/106002800303700208.

López-Torres, E., Süveges, Á., Peñas-LLedó, E. M., Doña, A., Dorado, P., LLerena, A., & Berecz, R. (2014). Liver enzyme abnormalities during antipsychotic treatment: A case report of risperidone-associated hepatotoxicity. Drug Metabolism and Drug Interactions, 29(2). https://doi.org/10.1515/dmdi-2013-0064.

Khorassani, F., Sousonis, F., & Lopez, L. V. (2020). Risperidone- and paliperidone-induced hepatotoxicity: a case report and literature review. American Journal of Health-System Pharmacy, 77(19), 1578–1584. https://doi.org/10.1093/ajhp/zxaa224.

Marwick, K. F. M., Taylor, M., & Walker, S. W. (2012). Antipsychotics and abnormal liver function tests. Clinical Neuropharmacology, 35(5), 244–253. https://doi.org/10.1097/wnf.0b013e31826818b6.